Abbott Receives CE Mark for Xience PRIME Drug-Eluting Stent
June 23, 2009 – Abbott said today it received CE mark (Conformite Europeenne) for its next-generation Xience PRIME Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.
The company plans to launch Xience PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter.
The modified design features of the stent and delivery system are intended to make it easier for physicians to deliver the stent to the treatment area, the company said. Xience PRIME utilizes the same drug and proven biocompatible polymer as Abbott's market-leading Xience V Everolimus-Eluting Coronary Stent System. In addition, it offers a novel stent design and a modified delivery system designed for greater flexibility and improved deliverability. Xience PRIME uses cobalt chromium technology, which allows for very thin struts while maintaining strength to support the vessel as well as excellent visibility under X-ray during the stent implantation procedure. Xience PRIME is based upon the proven design of the MULTI-LINK family of stents. Upon launch in Europe, Xience PRIME will be available in an expanded size matrix, including Xience PRIME SV for small vessels and Xience PRIME LL for long lesions.
Xience PRIME currently is an investigational device in the U.S. and not available for sale.
For more information: www.abbott.com
More like this
- Abbott Launches Next-Generation XIENCE PRIME DES in International Markets
- Abbott Begins Trial for Next-Generation Xience PRIME DES
- FDA Clears Xience Prime Coronary Stent
- XIENCE PRIME, XIENCE V Receive Indications in Europe to Treat Diabetes Patients
- Abbott's XIENCE V Cleared for Treatment of Coronary Artery Disease